"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...
Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...
Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
ClinBioNGS is a modular, fully containerized workflow implemented in Nextflow. It supports integrated analysis of DNA and RNA data, including multicaller small variant detection, copy number ...
Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic ...
CEO Dr Ilian Iliev and Steve Cook, CEO of EMVC portfolio company DName-iT, talked with Proactive's Stephen Gunnion about ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results